Mainz Biomed N.V. announced that its partner, GANZIMMUN Diagnostics, officially launched the enhanced ColoAlert colorectal cancer (CRC) screening test in Germany, starting January 2025. This launch makes the new version of the company’s screening test available to patients across Germany.
The enhanced ColoAlert, first introduced by Mainz Biomed in mid-2024, incorporates state-of-the-art advancements, including a proprietary DNA stabilizing buffer, designed to deliver accurate results even with varying sample volumes. This collaborative effort reinforces both companies’ commitment to advancing CRC prevention.
The launch coincides with Germany's updated national screening program, which now ensures equal access for men and women starting at age 50, addressing prior gender-based discrepancies. These unified guidelines are expected to drive broader participation in screening and enhance the integration of preventive measures in healthcare settings.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.